Episode 52: Prescription for Competition: Biosimilars are Changing Antitrust

A new class of lower-cost alternatives to brand name drugs has emerged: biosimilars. With the development of new technology, we have new complications for antitrust litigation and to explore these issues and more Nathan, Steve, and Brent are joined by antitrust expert Catia Twal.

Follow the "Of Significance" podcast on your preferred platform: Spotify, Apple, Amazon Music, YouTube.